Sunshine Biopharma settles dispute with former Nora Pharma president
The company will pay Malek Chamoun about CAD$1.5 million to resolve a disagreement tied to his former role at its Nora Pharma subsidiary.
Sunshine Biopharma Inc. disclosed in an 8-K that on July 8, 2026, it and its wholly-owned subsidiary Nora Pharma Inc. reached a settlement with Malek Chamoun, who previously served as Nora's president. The parties signed an agreement of transaction and mutual release to resolve their dispute.1
Under the terms, Sunshine Biopharma agreed to pay Chamoun CAD$1,500,000, or roughly US$1,058,565, as a full and final resolution of the matter.1
The company noted that the settlement document itself contains the complete terms, and that the full release agreement is attached as an exhibit to the filing.
The filing was signed on July 10, 2026 by CEO Dr. Steve N. Slilaty. No further details on the underlying dispute were provided in the filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.